Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD

Blood. 2017 Sep 7;130(10):1259-1266. doi: 10.1182/blood-2017-05-782870. Epub 2017 Jul 13.

Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is a common and poorly recognized complication of hematopoietic stem cell transplantation (HSCT) associated with excessive complement activation, likely triggered by endothelial injury. An important missing piece is the link between endothelial injury and complement activation. We hypothesized that neutrophil extracellular traps (NETs) mechanistically link endothelial damage with complement activation and subsequent TA-TMA. Neutrophil activation releases granule proteins together with double-stranded DNA (dsDNA) to form extracellular fibers known as NETs. NETs have been shown to activate complement and can be assessed in humans by quantification of dsDNA in serum. We measured levels of dsDNA, as a surrogate for NETs in 103 consecutive pediatric allogeneic transplant recipients at day 0, +14, +30, +60, and +100. A spike in dsDNA production around day +14 during engraftment was associated with subsequent TA-TMA development. Peak dsDNA production around day +14 was associated with interleukin-8-driven neutrophil recovery. Increased dsDNA levels at days +30, +60, and +100 were also associated with increased mortality and gastrointestinal graft-versus-host disease (GVHD). NETs may serve as a mechanistic link between endothelial injury and complement activation. NET formation may be one mechanism contributing to the clinical overlap between GVHD and TA-TMA.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Complement Activation / immunology*
  • DNA / blood*
  • Demography
  • Endothelial Cells / pathology*
  • Extracellular Traps / metabolism
  • Graft vs Host Disease / blood*
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / immunology*
  • Graft vs Host Disease / pathology
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Humans
  • Infant
  • Interleukin-8 / metabolism
  • Longitudinal Studies
  • Neutrophils / metabolism
  • Receptors, Interleukin-8A / metabolism
  • Receptors, Interleukin-8B / metabolism
  • Thrombotic Microangiopathies / blood*
  • Thrombotic Microangiopathies / etiology
  • Thrombotic Microangiopathies / immunology*
  • Thrombotic Microangiopathies / therapy
  • Treatment Outcome
  • Young Adult

Substances

  • Interleukin-8
  • Receptors, Interleukin-8A
  • Receptors, Interleukin-8B
  • DNA